Wei Feng, M.D.
- Thyroid Cancer
- Pituitary Disorders
- Adrenal Disease
- Lipid Disorder
Wei Feng, M.D., is a board certified endocrinologist with expertise in many areas such as diabetes, thyroid, pituitary, osteoporosis, PCOS, obesity, lipid disorder, and adrenal disease. She has been a staff physician at the Department of Clinical Diabetes, Endocrinology, and Metabolism at City of Hope since 1998.
Born in China, Dr. Feng obtained her medical degree at University of Heidelberg in West Germany in 1987. After completing residency training in internal medicine at University of Memphis in Tennessee, she sought endocrine fellowship training at Cedars Sinai Medical Center. She has diverse clinical experience being hospitalist for a year in 1992 after completing residency training at Memphis Regional Medical Center and a faculty member in the Division of General Internal Medicine at USC between 1995 and 1998.
Dr. Feng entered private endocrine practice in year of 2005 in Pasadena while maintaining a part-time position at City of Hope. Now she devotes all her time to the practice of endocrinology at the South Pasadena Cancer Center, which is fully affiliated with the Department of Clinical Diabetes and Endocrinology at the City of Hope.; Dr. Feng has been a principal investigator for several clinical trials involving long term studies of intervention for high-risk diabetic patients to prevent cardiovascular events, treatment for diabetic peripheral neuropathy, islet cell transplant program, and new treatment options for type 1 and type 2 diabetes.
- 2010 - present, Physician, City of Hope, South Pasadena, CA
- 1998 - present, Assistant Clinical Professor, Department of Clinical Diabetes, Endocrinology and Metabolism, City of Hope, Duarte, CA
- 2005 - 2010, Physician, Private Practice, Pasadena, CA
- 1995 - 1998, Clinical Assistant Professor in Medicine, Division of General Internal Medicine, University of Southern California, Los Angeles, CA
- 1992 - 1993, Instructor in Medicine, Division of General Internal Medicine, University of Tennessee, Memphis, TN
- 1987, University of Heidelberg School of Medicine, West Germany, M.D.
- 1993-1995, Cedars-Sinai Medical Center, Los Angeles, CA, Endocrinology and Metabolism, Fellowship
- 1990-1992, University of Tennessee, Memphis, TN, Internal Medicine, Residency
PARTIAL LIST OF PUBLICATIONS
Jean Huang, Horng-Yih Ou, Rudruidee Karnchanasorn , Raynold Samoa , Lee-Ming Chuang, Ken C. Chiu, Wei Feng: Fasting Plasma Glucose >126 mg/dl Misses Almost 50 % of Diabetes Mellitus as compared to 2- Hour Postchallenged Plasma Glucose >200 mg/dL. Poster Presentation, (2013) The Endocrine Society's 95th Annual Meeting & Expo.
James Lin, Rudruidee Karnchanasorn, Horng-Yih Ou, Jean Huang, Wei Feng, Raynold Samoa , Lee-Ming Chuang, Ken C. Chiu: hepatitis A and B are associated with an Increased Risk for Diabetes Mellitus. Poster Presentation, (2013) The Endocrine Society's 95th Annual Meeting & Expo.
Horng-Yih Ou, Rudruidee Karnchanasorn Jean Huang, Wei Feng, Raynold Samoa , Lee-Ming Chuang, Ken C. Chiu: Aging is associated with Progressive Increase in TSH and Progressive Increase in Free T3 and Total T3, but not Free T4 and and Total T4 while Diabetes Mellitus has No Significant Impact on Thyroid Function. Poster Presentation, (2013) The Endocrine Society's 95th Annual Meeting & Expo.
Claire Park, Horng-Yih Ou, Jean Huang, Wei Feng, Raynold Samoa , Lee-Ming Chuang, Ken C. Chiu, Rudruidee Karnchanasorn: Comparison of Hb A1 C>6.5 % and 2-Hour Plasma Glucose >200 mg/dl Criteria in Diagnosis of Diabetes Mellitus. Poster Presentation, (2013) The Endocrine Society's 95th Annual Meeting & Expo.
Rudruidee Karnchanasorn, Jean Huang, Horng-Yih Ou, Wei Feng, Raynold Samoa , Lee-Ming Chuang, ken C. Chiu: 2-Hour Plasma Glucose Increases Much Faster with Age in Abnormal Glucose Tolerant Subjects Than Glucose Tolerant Subjects, While No Difference in Fasting Plasma Glucose. Poster presentation. (2013) 73rd ADA Scientific Sessions.
Horn-Yih OU, Jean Huang, Rudruidee Karnchaasorn, Wei Feng, Raynald Samona, Ken C Chiu, Lee-Ming Chuang: A1 c >6.5 % Missed the Majority of Diabetic Patients Defined by Plasma Glucose. Poster Presentation. (2013) 73rd ADA Scientific Sessions.
Feng Miao, D.Smith, L. Zhang, A. Min, Wei Feng, Rama Natarajan: Lymphocytes from patients with type 1 diabetes display a distinct profile of chromatin histone H3 lysine 9 dimethylation: an epigenetic study in diabetes Diabetes (2008) Dec;57(12):3189-98.
Fariba Rahnema, Sam Pourbabak, Mohamad Al-Sayed, Everett Chang, Connie Kwan, Wei Feng, Ken C. Chiu: Circulating high Molecular Weight Adiponectin Level are Related to Obesity but not to Insulin Sensitivity in Health and Glucose Tolerant Caucasians. (2007) ADA Annual Scientific Sessions.
Prasanth N. Surampudi, Mohamad Al-Sayed, Everett Chang, Connie Kwan, Wei Feng, Ken Chiu: Failure of Beta Cell Compensation in Glucose Tolerance Subjects with Increasing Insulin Resistance. (2007) ADA 67th Annual Scientific Sessions.
Ken C. Chiu, Horng-Yih Ou, Ta-Jen Wu, Everett Chang, Connie Kwan, Wei Feng: The Impact of Obesity on the Relationship of serum 25-Hydrosyvitamin D with Insulin Sensitivity and Beta Cell Function. (2007) ADA 67th Annual Scientific Sessions.
Yen, Chu, and Feng: Paraneoplastic syndrome in cancer: case 3. Parathyroid Hormone-Related Hypercalcemia in Cholangiocarcinoma. JCO Jun 1 (2004); 2244-2245.
Diabetes Prevention Trial-Type 1 Diabetes Study Group [Feng W-Study Group Member]. Effects of Insulin in Relatives of Patients with Type 1 Diabetes Mellitus. New England Journal of Medicine (2002) 346: 1685-1691.
Yu L, Cuthbertson DDM Maclaren N, Jackson R, Palmer JP, Orban T, Eisenbarth Gs, Krischer JP, DPT-1 Participating Investigators [Feng W-Study group member]. Expression of GAD65 and Islet Cell Antibody (ICA512) Auto antibodies Among Cytoplasmic ICA+ Relatives Is Associated With Eligibility for the Diabetes Prevention Trial-Type 1. Diabetes (2001) 50:1735-1740.
Chase HP, Cuthbertson DD, Dolan LM, Kaufman F, Krischer JP, Schatz DA, White NH, Wilson DM, Wolfsdorf J, The Diabetes Prevention Trial-Type 1 Study Group [Feng W-Study group member]. First-phase Insulin Release during The Intravenous Glucose Tolerance Test As A Risk Factor For Type 1 Diabetes. Journal of Pediatrics (2001); 244-249
Greenbaum CJm Cuthbertson D, Krischer JP, and the Diabetes Prevention Trial of Type 1 Diabetes Study Group [Feng W, study Group Member]. Type 1 Diabetes Manifested Solely by 2-h Oral Glucose Tolerance Test Criteria. Diabetes (2001); 50:470-476.
- American Association of Clinical Endocrinologists
- Endocrine Society